Insight

Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology

Photo from annalsofoncology.org

May 9, 2024, 11:35

Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology

Quoting Vivek Subbiah on X: .

“A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results – Annals of Oncology.”

Read further.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Annals of Oncology Breast Cancer cancer Erika Hamilton OncoDaily Oncology Sarah Cannon Research Institute SERD camizestrant SERENA-1 SERENA-1 monotherapy results Vivek Subbiah

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology